2026-04-05T10:51:11Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/81532025-10-24T10:42:45Zcom_2072_378070com_2072_378040col_2072_378092

Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology Trigo, José Manuel Garcia-Cosio, Monica García‑Castaño, Almudena Gomà, Montserrat Mesia, Ricard Ruiz‑Bravo, Elena Braña Garcia, Irene Alberola Ferranti, Margarita Marcadors bioquímics Glàndules salivals - Càncer Cap - Càncer DISEASES::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms DISEASES::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms::Mouth Neoplasms::Salivary Gland Neoplasms CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de cabeza y cuello ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de cabeza y cuello::neoplasias de la boca::neoplasias de las glándulas salivales COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales Epstein Barr virus; Prognosis; Response to treatment Virus de Epstein Barr; Pronóstico; Respuesta al tratamiento Virus d'Epstein Barr; Pronòstic; Resposta al tractament The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein–Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers. SEOM and SEAP acknowledge the financial support for this project in the form of unrestricted collaboration in the logistics from AstraZeneca. 2025-10-24T10:42:45Z 2025-10-24T10:42:45Z 2022-09-12T09:54:26Z 2022-09-12T09:54:26Z 2022-10 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/8153 Clinical and Translational Oncology;24 https://doi.org/10.1007/s12094-022-02856-1 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Springer Scientia